Shares in AIM-listed biotechnology firm Silence Therapeutics (LON:SLN) rose by 9.77% to 483p (as of 15:25 BST) after announcing that it remains on track to submit an IND application to the FDA for its SLN360 asset later this year. The company also said that it would be applying to the U.S Securities and Exchange Commission to facilitate a listing of dispositional shares in the US.
Additionally, Ian Ross was appointed full time Executive Chairman while the search for an optimal CEO candidate continues. Mr Ross commented: “Since I returned to Silence last year, the Company has advanced its innovative product pipeline, secured three validating big pharma partnerships, significantly strengthened its cash position and built a strong and experienced management team, which has proven it can execute a plan. The Company is at a critical stage of its development and I am very excited to be at the helm at this important time“.